Dexcom Inc
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000NWTZR5
DXCM
Dexcom Inc
GICS: 35101010
·
Sektor: Healthcare
·
Sub-Sektor: Medical Devices
NAME
Dexcom Inc
ISIN
US2521311074
TICKER
DXCM
MIC
XNAS
REUTERS
DXCM.OQ
BLOOMBERG
DXCM US
F&G:
60
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mi., 30.07.2025
DexCom
US2521311074
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights:
Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis.
U.S. revenue grew 15% and international revenue grew 16% on a reported b...
Mi., 30.07.2025
DexCom
US2521311074
Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.*
This press release features multimedia. Vi...
Mo., 28.07.2025
DexCom
US2521311074
DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United States, following the feature’s launch on Dexcom G7 earlier this year.
This press release features multimedia. View the full rel...
Do., 17.07.2025
DexCom
US2521311074
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/...
Di., 01.07.2025
DexCom
US2521311074
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently w...
Mi., 18.06.2025
DexCom
US2521311074
DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 4...
Di., 10.06.2025
DexCom
US2521311074
Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain D...
Di., 13.05.2025
DexCom
US2521311074
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202...
Do., 01.05.2025
DexCom
US2521311074
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights:
Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis.
U.S. revenue grew 15% and international revenue grew 7% on a reported basis...
Di., 22.04.2025
DexCom
US2521311074
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its ros...
Informationen zu Product Placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
